Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

l mode of action, including its magnetic resonance imaging detectability, provides the opportunity for Xcytrin to be used in a broad range of cancers. In previously conducted randomized trials, Xcytrin combined with whole brain radiation therapy (WBRT) has been shown to prolong time to neurologic progression in patients with brain metastases from NSCLC. Xcytrin's non-overlapping toxicity makes it an appealing agent to use in combination with standard chemotherapy regimens.

The target for Xcytrin is the enzyme thioredoxin reductase, which is frequently overexpressed in lung cancer cells. This enzyme has been shown to confer to cancer cells characteristics of aggressive tumor growth and resistance to chemotherapy. First-line therapy for advanced NSCLC includes combination chemotherapy using drugs such as carboplatin, cisplatin, Gemzar(R), taxanes and others. Currently approved agents for second-line treatment of NSCLC include Alimta, Tarceva(R) and Taxotere.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. A New Drug Application for use of Xcytrin in combination with WBRT for treatment of brain metastases from NSCLC was filed with the Food and Drug Administration in April 2007. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. In addition, more information about advocacy on behalf of Xcytrin can be found at




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/30/2014)... 2014  Tasly Pharmaceuticals, Inc., the world,s leader ... today the launch of Deepure. Deepure ... men and women concerned with supporting their overall ... age while helping keep their health care cost ... herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and ...
(Date:9/30/2014)... 30, 2014 Aileron Therapeutics, Inc. - ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - Product ... the Aileron Therapeutics, Inc.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Aileron Therapeutics, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... 2014 According to ... by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments ... Application (Immunology, Oncology) & by End User ... MarketsandMarkets, provides a detailed overview of the ... trends, and strategies impacting the global glycomics ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... 9 Peptimmune, Inc., a privately,held biotechnology ... peptide copolymer program at both the 17th ... FOCIS 2008 in Boston, MA. The Company ... study involving,healthy, male adult volunteers following SC ...
... juice has ... NEW YORK, June 9 CherryPharm -- a proprietary,all-natural ... of,cherries -- has been shown to improve aspects of sleep, ... This double-blind,placebo controlled clinical trial tested the effectiveness of CherryPharm,in ...
Cached Medicine Technology:Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings 2Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings 3CherryPharm First All-Natural Food to Improve Sleep 2
(Date:10/2/2014)... -- Genes may interact with stress to trigger heart disease ... risk occurs in about 13 percent of people, but only ... people reduce their heart disease risk through simple measures such ... Duke University researchers said. The study authors analyzed genetic ... between variations in the EBF1 gene and higher levels of ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... roses -- literally -- may face an increased risk of dying ... study of over 3,000 older Americans, researchers found those who were ... more than three times as likely to die in the next ... In fact, anosmia -- the inability to distinguish odors -- was ...
(Date:10/1/2014)... developed a model that could help to predict a ... from their very first psychotic episode. , The model ... symptoms, cognitive abilities, MRI scans of the brain,s structure, ... the lead up to World Mental Health Day (10 ... Professor Bernhard Baune , says the model is a ...
(Date:10/1/2014)... the human eye, the brain of a rat and ... technology, says a QUT leading robotics researcher. , ... says the new study uses new computer algorithms to ... or tunnels. , "This is a very Frankenstein type ... halves of a thing together because we,re taking the ...
(Date:10/1/2014)... encourages people to keep their "eyes on the prize" ... When walking, staying focused on a specific target ahead ... help people walk there faster, psychology researchers have found. ... looking around the environment naturally, offers a new strategy ... less interested in exercise if physical activity seems daunting, ...
Breaking Medicine News(10 mins):Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Predicting the future course of psychotic illness 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... suffered cardiac death would have their bodies prepared for ... Australian Health Ethics Committee that is working on organ ... patients who are certain to die after experiencing cardiac ... heart, liver lungs and kidneys begin to deteriorate immediately ...
... help Alzheimer's patients interact and communicate with others, finds ... Newcastle General Hospital studied the benefits of dolls after ... from her son, reported the online edition of BBC ... can lose their intellectual, social and emotional abilities over ...
... major public health threat posed by antibiotic-resistant bacteria, ... (UCSD) are launching a new program to develop ... and testing, to clinical trials. ,"UCSD ... necessary expertise to fight this urgent medical problem," ...
... discovered around 1994 which has the ability to perform multi ... other crucial physiological activities. , But the ... out these metabolic activities were not known till date. Now, ... University have identifies the mode in which Leptin carries out ...
... University, Doug Goodin, makes use of satellite imagery to ... //changes on human health and food security. ... types of data, to monitor and predict the spread ... discussed this subject at the workshop, "Contributions of Remote ...
... men for a good 14 years has revealed that regular ... body weight has an impact in cutting down the risks ... co-author of the study, said "Even though erectile problems were ... clear that heart disease and ED share many of the ...
Cached Medicine News:Health News:New UCSD Program to Fight Drug-Resistant Bacteria 2Health News:New UCSD Program to Fight Drug-Resistant Bacteria 3Health News:New UCSD Program to Fight Drug-Resistant Bacteria 4Health News:How Does Leptin Work? 2Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2
... Disease ELISA kits utilize ... Also included in each ... negative controls, serum diluent, ... Use an ELISA plate ...
... (PCR) technology, the worlds leading nucleic acid ... Roches blood screening assays and other diagnostic ... unique regions of genetic material to be ... to detectable levels) in only a few ...
... Continuing to lead the market in ... WAVE IABP is a whole new first ... optic technology coupled with a physiologically based ... support with unprecedented timing accuracy. Second ...
... worlds first truly automated immunohistochemistry ... a whole new level of ... modularity and ease of operation ... NexES Systems automated technology provides ...
Medicine Products: